Catalent shares jump as long-delayed results clear 'low bar'
Reuters
Published Jun 12, 2023 07:05AM ET
Updated Jun 12, 2023 01:06PM ET
By Bhanvi Satija
(Reuters) - Catalent (NYSE:CTLT)'s shares shot up 12% on Monday as the contract drug manufacturer posted third-quarter revenue ahead of estimates after a long delay caused by persistent production issues at its major facilities.
The company reported a larger-than-expected quarterly loss and cut its annual revenue forecast for the second time, but strength in its biologics unit drove quarterly sales past tempered Wall Street estimates.
Catalent's "results cleared an admittedly low bar", Stephens analyst Jacob Johnson said.
"After a number of shoes dropping and a lot of noise recently, today was a good first or second step."
The company had delayed its quarterly results report thrice in less than a month, hit by production snags at three of its key facilities, including in Brussels, where it does filling work for Novo Nordisk (NYSE:NVO)'s obesity drug Wegovy.
The issues drove up expenses and further hampered the company's cost-cutting efforts that were already under pressure from regulatory inspections and subsequent corrective actions.
Catalent's shares have fallen nearly 40% since it first disclosed manufacturing issues in April.
On Monday, however, CEO Alessandro Maselli told analysts on a conference call that he expects strong operational performance at the Maryland site, where Catalant produces raw material for mRNA-based therapies and gene therapies.
"Our financial performance will eventually follow these operational improvements," Maselli added.
Catalent reported a third-quarter loss of 9 cents per share, compared with Wall Street estimates for a loss of 3 cents, according to IBES data from Refinitiv.
The company will also amend its 2022 results filing with a $26 million deduction caused by a revenue recognition error at its Bloomington plant.
The contract drug manufacturer cut its fiscal 2024 revenue forecast to a range of $4.23 billion to $4.33 billion.
Quarterly sales of $1.04 billion beat estimates of $952.7 million.
(This story has been corrected to say Catalent does filling work only for Novo's obesity drug at the Brussels site, not Indiana site, in paragraph 5)
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.